Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 


Online Report Subscribers, Click Here
Pricing and Ordering Information

U.S. Markets for Diabetes Management Products
Report #A376 - May 2009
247 Pages – 78 Exhibits – 13 Key Company Profiles


Diabetes affects nearly 24 million people in the U.S. and an estimated 246 million adults worldwide and is the 5th leading cause of death by disease in the U.S. It is also one of the most expensive diseases, costing the U.S. healthcare system more than $130 billion per year. In order to constrain spiraling healthcare costs and limit the progression of full-blown type 2 diabetes and its complications among an aging and increasingly obese population, the development of more affordable and effective diabetes management (self-testing and treatment) products has become a top priority not only in the U.S., but worldwide.

Due to demographics, strong demand, and other factors, the diabetes management products market—including blood glucose monitoring systems, insulin injection devices and insulin pumps, insulin therapies and oral and injectable diabetes drugs—has become one of the largest medical device and pharmaceutical markets in the U.S., totaling more than $15 billion. As the population of diabetics continues to increase, the market is expected to continue to grow at a double-digit rate over the next five years, reaching nearly $28 billion by 2013.

Monitoring glucose levels is critical for the management of diabetes and new and improved portable, less costly, easy-to-use, accurate and virtually painless blood glucose monitoring systems are now available. In addition, new and improved insulin pens are enabling less painful and burdensome daily injection of insulin, helping to spur insulin therapy sales.

In the blood-glucose lowering treatment area, several new drugs, such as Byetta and Januvia have exhibited good safety and efficacy profiles and have reached blockbuster status over the last few years, despite the economic troubles in the U.S. and worldwide. In addition, a substantial number of emerging diabetes drugs are under clinical study by dozens of startup companies and large pharmaceutical companies; with several expected to enter the U.S. market over the next few years. Next-generation diabetes drug therapies are promising to addressing the strong need for safer, long-term blood glucose control, used as monotherapies or in combination with insulin or other oral diabetes drug therapies.

This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. diabetes products market. Product areas include: self-testing blood glucose monitoring systems, continuous blood glucose monitoring systems, insulin therapies, insulin injection devices, insulin pumps, injectable/oral diabetes drugs, and emerging diabetes drugs and technologies, including pancreatic islet cell transplantation.

Ordering Information

Title

 Report# Publication
Date		 List Price

U.S. Markets for Diabetes Management Products

A376

May 2009

$4,750
Order Online:
Single User only (Please call for corporate subscription pricing)		 PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

 

EXECUTIVE SUMMARY

i.    Types of Diabetes

ii.    Diagnosis

iii.   Management and Treatment

iv.   Total Diabetes Management Products Market

v.   Methodology

 

Exhibit ES-1:    2007, Selected Diabetes Statistics

Exhibit ES-2:    Diagnosis of Diabetes and Pre-Diabetes

Exhibit ES-3:    Diabetes Management Products, Combined Market Forecast, 2008-2013

Exhibit ES-4:    2013, Diabetes Management Products, Estimated Share of Sales, by Segment

 

1. CLINICAL OVERVIEW

1.1 Types of Diabetes

1.2 Diagnosis

1.3 Management and Treatment

 

Exhibit 1-1:      2007, Selected Diabetes Statistics

Exhibit 1-2:      Diagnosis of Diabetes and Pre-Diabetes

Exhibit 1-3:      Diabetes Complications

 

2. BLOOD GLUCOSE MONITORING SYSTEMS

2.1 Glucose Monitoring Systems

2.1.1 Abbott Laboratories

2.1.2 Bayer HealthCare/Bayer

2.1.3 Home Diagnostics

2.1.4 LifeScan/Johnson & Johnson

2.1.5 Roche Diagnostics/F. Hoffmann-La Roche

2.1.6 Others

2.2 Continuous Glucose Monitoring Systems

2.2.1 Abbott Laboratories

2.2.2 DexCom

2.2.3 Medtronic

2.3 Lancing Devices

2.3.1 Abbott Laboratories

2.3.2 Bayer HealthCare/Bayer

2.3.3 Home Diagnostics

2.3.4 LifeScan/Johnson & Johnson

2.3.5 Roche Diagnostics/F. Hoffmann-La Roche

2.3.6 Others

2.4 Glucose Monitoring Systems under Development

2.4.1 Echo Therapeutics

2.4.2 Epinex Diagnostics

2.4.3 Sensors for Medicine and Science

2.4.4 Solianis Monitoring

2.4.5 Others

2.5 Market Analysis

2.6 Competitive Analysis

 

Exhibit 2-1:      2009, Selected Blood Glucose Monitoring Systems

Exhibit 2-2:      Abbott Laboratories’ FreeStyle and Precision Xtra Blood Glucose Monitoring Systems

Exhibit 2-3:      Bayer HealthCare’s Breeze2 and Contour Blood Glucose Meters

Exhibit 2-4:      Home Diagnostics’ TRUE2go and TRUEresult Blood  Glucose Meters

Exhibit 2-5:      LifeScan’s OneTouch UltraMini Blood Glucose Meter

Exhibit 2-6:      LifeScan’s OneTouch UltraSmart Blood Glucose Meter

Exhibit 2-7:      LifeScan’s OneTouch UltraLink and Medtronic’s MiniMed Paradigm REAL-Time Blood Glucose Monitoring Systems

Exhibit 2-8:      Roche Diagnostics’ ACCU-CHEK Compact Plus Blood Glucose Meter

Exhibit 2-9:      Roche Diagnostics’ ACCU-CHEK Aviva and Advantage Blood Glucose Meters

Exhibit 2-10:    AKRAY USA’s PocketChem EZ and GLUCOCARD Blood Glucose Meters

Exhibit 2-11:    The ReliOn Ultima Blood Glucose Monitoring System

Exhibit 2-12:    2009, Selected Continuous Glucose Monitoring Systems

Exhibit 2-13:    Abbott Laboratories’ FreeStyle Navigator Continuous Blood Glucose Monitoring System

Exhibit 2-14:    DexCom’s SEVEN PLUS Continuous Blood Glucose Monitoring System

Exhibit 2-15:    Medtronic’s Guardian REAL-Time Continuous Blood Glucose Monitoring System

Exhibit 2-16:    2009, Selected Lancing Devices

Exhibit 2-17:    Bayer HealthCare’s MICROLET2 and MICROLET VACULANCE  Lancing Devices

Exhibit 2-18:    Home Diagnostics’ Gentle Draw Lancing Device

Exhibit 2-19:    LifeScan’s OneTouch Lancing Devices

Exhibit 2-20:    2009, Selected Glucose Monitoring Technologies under Development

Exhibit 2-21:    Echo Therapeutics’ Symphony Transdermal Continuous Glucose Monitoring System

Exhibit 2-22:    Epinex Diagnostics’ G1A Rapid Diabetes Monitoring Index Test Prototype

Exhibit 2-23:    Sensors for Medicine and Science’s SMSI Glucose Sensor

Exhibit 2-24:    Blood Glucose Monitoring Systems, Market Forecast, 2008-2013

Exhibit 2-25:    2008, Blood Glucose Monitoring Systems Market, Share by Supplier

 

3. DIABETES DRUG THERAPY

3.1 Insulin Therapy

3.1.1 Eli Lilly

3.1.1.1 Humalog

3.1.1.2 Humulin

3.1.2 Novo Nordisk

3.1.2.1 Levemir

3.1.2.2 NovoLog

3.1.2.3 NovoLog Mix 70/30

3.1.3 Sanofi-aventis

3.1.3.1 Apidra

3.1.3.2 Lantus

3.2 Injectable Diabetes Drugs

3.2.1 Amylin Pharmaceuticals and Eli Lilly

3.2.1.1 Byetta

3.2.1.2 Symlin

3.3 Oral Diabetes Drugs

3.3.1 Bayer HealthCare/Bayer

3.3.1.1 Glucobay

3.3.2 Bristol-Myers Squibb

3.3.2.1 Glucophage

3.3.2.2 Glucovance

3.3.3 GlaxoSmithKline

3.3.3.1 Avandia

3.3.3.2 Avandamet

3.3.3.3 Avandaryl

3.3.4 Merck

3.3.4.1 Januvia

3.3.4.2 Janumet

3.3.5 Novartis

3.3.5.1 Starlix

3.3.6 Novo Nordisk

3.3.6.1 Prandin

3.3.7 Pfizer

3.3.7.1 Glucotrol

3.3.7.2 Glyset

3.3.8 Sanofi-aventis

3.3.8.1 Amaryl

3.3.9 Takeda Pharmaceuticals North America/ Takeda Pharmaceutical Company

3.3.9.1 Actos

3.4 Generic Diabetes Drugs

3.5 Diabetes Drugs under Development

3.5.1 Oral and Sublingual Insulin

3.6 Aborted Diabetes Drugs

3.7 Market Analysis

3.7.1 Insulin Therapy Products

3.7.1.1 Market Forecast

3.7.1.2 Competitive Analysis

3.7.2 Injectable and Oral Diabetes Drug Therapy

3.7.2.1 Market Forecast

3.7.2.2 Competitive Analysis

 

Exhibit 3-1:      2009, Selected Diabetes Drugs

Exhibit 3-2:      2009, Selected Types of Insulin

Exhibit 3-3:      Eli Lilly’s Humulin Insulin Product Line

Exhibit 3-4:      Byetta’s Effects on Blood Glucose

Exhibit 3-5:      Symlin’s Mechanisms of Action

Exhibit 3-6:      The SymlinPen 120 Injector Device

Exhibit 3-7:      Januvia’s Mechanism of Action

Exhibit 3-8:      2009, Selected Diabetes Drugs in Late-Stage Development

Exhibit 3-9:      Diabetes Drugs under Development

Exhibit 3-10:    Insulin Therapy Products, Market Forecast, 2008-2013

Exhibit 3-11:    2008, Insulin Therapy Products Market, Share by Supplier

Exhibit 3-12:    Injectable and Oral Diabetes Drug Therapy Products, Market Forecast, 2008-2013

Exhibit 3-13:    2008, Injectable and Oral Diabetes Drug Therapy Products Market, Share by Supplier

 

4. INSULIN DELIVERY DEVICES

4.1 Insulin Syringes

4.1.1 Abbott Laboratories

4.1.2 BD

4.2 Insulin Pens

4.2.1 Eli Lilly

4.2.2 Novo Nordisk

4.2.3 sanofi-aventis

4.2.4 Owen Mumford

4.3 External Insulin Pump Systems

4.3.1 Animas/Johnson & Johnson

4.3.2 Smiths Medical/Smiths Group

4.3.3 Insulet

4.3.4 Medtronic

4.3.5 Roche Diagnostics/F. Hoffmann-La Roche

4.3.6 Others

4.4 Insulin Jet Injectors

4.5 Market Analysis

4.5.1 External Insulin Pump Systems

4.5.1.1 Market Forecast

4.5.1.2 Competitive Analysis

4.5.2 Insulin Pens and Syringes

4.5.2.1 Market Forecast

4.5.2.2 Competitive Analysis

 

Exhibit 4-1:      2009, Selected Insulin Syringes

Exhibit 4-2:      Abbott Laboratories’ Precision Sure-Dose Insulin Syringe

Exhibit 4-3:      The BD Ultra-Fine Insulin Syringe

Exhibit 4-4:      BD’s Safety-Engineered Insulin Syringes

Exhibit 4-5:      BD’s Ultra-Fine Insulin Pen Needles

Exhibit 4-6:      2009, Selected Insulin Pens

Exhibit 4-7:      Eli Lilly’s Line of Prefilled Insulin Pens

Exhibit 4-8:      Eli Lilly’s HumaPen MEMOIR and LUXURA HD Insulin Pens

Exhibit 4-9:      Novo Nordisk’s FlexPen Insulin Pens

Exhibit 4-10:    Novo Nordisk’s NovoPen 4 Insulin Pens

Exhibit 4-11:    Sanofi-aventis’ Lantus SoloStar Insulin Pen

Exhibit 4-12:    Owen Mumford’s Autopen Insulin Pen

Exhibit 4-13:    Diagram of External Insulin Pump Therapy

Exhibit 4-14:    2009, Selected External Insulin Pump Systems

Exhibit 4-15:    Animas’ OneTouch Ping Glucose Management System

Exhibit 4-16:    Smiths Medical’s Deltec Cozmo Insulin Pump

Exhibit 4-17:    Insulet’s OmniPod Insulin Management System

Exhibit 4-18:    Medtronic’s MiniMed Paradigm Insulin Pump

Exhibit 4-19:    Roche Diagnostics’ ACCU-CHEK Spirit Insulin Pump

Exhibit 4-20:    Nipro Diabetes Systems’ Amigo Insulin Pump

Exhibit 4-21:    Activa Brand Products’ AvantaJet Insulin Injector

Exhibit 4-22:    External Insulin Pump Systems, Market Forecast, 2008-2013

Exhibit 4-23:    2008, External Insulin Pump Systems Market, Share by Supplier

Exhibit 4-24:    Insulin Pens and Syringes, Market Forecast, 2008-2013

Exhibit 4-25:    2008, Insulin Pens Market, Share by Supplier

Exhibit 4-26:    2008, Insulin Syringes Market, Share by Supplier

 

5. EMERGING TECHNOLOGIES

5.1 Pancreatic Islet Cell Transplantation

5.1.1 Cerco Medical

5.1.2 Geron

5.1.3 MicroIslet

5.1.4 Novocell

5.1.5 Opexa Therapeutics

5.1.6 Senesco Technologies

5.1.7 Sernova

5.2 Umbilical Cord Blood Transfusion

 

Exhibit 5-1:      Diagram of the Pancreas and Islets of Langerhans

Exhibit 5-2:      Pancreatic Islet Transplantation Procedure

Exhibit 5-3:      Edmonton Protocol and Research Development

Exhibit 5-4:      2009, Selected Emerging Stem Cell and Pancreatic Islet Cell Transplantation Technologies

Exhibit 5-5:      Cerco Medical’s Definition of a Bio-Artificial Pancreas and Islet Sheet Technology

Exhibit 5-6:      MicroIslet's Encapsulated Porcine Islet Technology

Exhibit 5-7:      Opexa Therapeutics’ Monocyte-Derived Stem Cell Technology

 

6. COMPANY PROFILES

6.1       Abbott Laboratories

6.2       Amylin Pharmaceuticals, Inc.

6.3       Bayer HealthCare AG/Bayer AG

6.4       Home Diagnostics, Inc.

6.5       Johnson & Johnson

6.6       Eli Lilly and Company

6.7       Medtronic, Inc.

6.8       Merck & Company, Inc.

6.9       Novo Nordisk AS

6.10     Roche Diagnostics/F. Hoffmann-La Roche LTD

6.11     sanofi-aventis

6.12     Teva Pharmaceutical Industries LTD

6.13     Takeda Pharmaceuticals North America/Takeda Pharmaceutical Company

 

APPENDIX:  COMPANY LISTING

 

 

 

To order reports or obtain information about special pre-publication offers from within the U.S., contact sales@medtechinsight.com. From outside the U.S., contact internationalsales@medtechinsight.com. You can also call 1.949.453.0071 (or toll-free within the U.S. at 1.888.290.2225) or fax 1.949.453.0072.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home